Enliven Therapeutics (ELVN) Stock: Buy, Sell, or Hold?
ELVN - Enliven Therapeutics, Inc. Common Stock
$41.80
-0.02 (-0.06%)
▼
5d:
+6.27%
30d:
-9.32%
90d:
-21.07%
BUY
HIGH Confidence
Analysis Updated: Oct 22, 2026 12:00 AM ET
Earnings: Nov 11, 2026
19d
Get Alerted When ELVN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: ELVN shows strong fundamentals and good volume confirmation. Solid entry point despite slightly low pricing.
✅ BUY SIGNAL: ELVN shows strong fundamentals and good volume confirmation. Solid entry point despite slightly low pricing.
In-depth Analysis How we analyze
Valuation Analysis: ELVN is currently trading at $41.80, which is considered slightly low relative to its 30-day fair value range of $40.23 to $49.06.
Technical Outlook: Technically, ELVN is showing sideways momentum. The price is approaching resistance at $42.92. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: ELVN scores 73/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $74.62 (+78.4%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, ELVN is showing sideways momentum. The price is approaching resistance at $42.92. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: ELVN scores 73/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $74.62 (+78.4%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$40.23 -
$49.06
Company Quality Score
60/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
94.7%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Strong technical setup (73/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 78.4% below Wall St target ($74.62)
- BULLISH: Bottoming setup score 73/100 — corrected, stabilizing, and turning up
Trading Range Analysis
30-Day Trading Range
$40.23 -
$49.06
Current vs Trading Range
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$36.96
Resistance Level
$42.92
Current Trend
Sideways
Technical data as of
Oct 22, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-18.05
Wall Street Target
$74.62
(+78.4%)
Share & Embed Analysis
Last updated: October 22, 2026 3:43 PM ET
Data refreshes hourly during market hours. Next update: 4:43 PM
Data refreshes hourly during market hours. Next update: 4:43 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ELVN showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
RVMD
Revolution Medicines Inc |
STRONG BUY
24 analysts |
$258 | 57 HOLD |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
21 analysts |
$95 | 59 HOLD |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$72 | 56 HOLD |
|
JANX
Janux Therapeutics Inc |
STRONG BUY
18 analysts |
$36 | 49 HOLD |
|
STTK
Shattuck Labs Inc |
STRONG BUY
12 analysts |
$15 | 67 BUY |
Advanced ELVN Option Strategies
Professional options setups generated by AI based on today's ELVN price and gamma walls.
